The retreat of corporate venture funding?
Many corporate-backed funds remain enthusiastic venture investors, but some might be hitting the brakes.
Stock market correction sends biopharma back to the start of 2021
Covid-19 vaccine developers stand out as global drug stocks tread water in the first quarter.
Quiet times return for biopharma takeouts
The first quarter of 2021 saw fewer deals than any in recent memory.
Big pharma freshens up
Reliance on established drugs lessened for most large drug makers last year, but staleness is creeping in at Merck and Bristol.
The flotation window stays open, for now
The first quarter of 2021 sets a new record, but the tide might be starting to turn.
Biotech venture financing starts the year with a bang
With a record $7.1bn raised in the first quarter the cash available to private drug developers shows no signs of drying up.
Venture-backed medtechs rush for the exit
A lot of money is sloshing around, and medical device start-ups are reaping the benefits.
Despite Imfinzi, US accelerated approvals surge
More and more drugs are being approved conditionally on flimsy data, and Imfinzi is just the second to be pulled after failing a confirmatory trial.
